Daniela Di Carlo, Lisa Lyngsie Hjalgrim, Beatrice Coppadoro, Michela Casanova , Andrea Ferrari, Veronique Minard-Colin , Hans Merks , Gianni Bisogno, EJC Paediatric Oncology. Volume 5, June 2025, 100221
A clinical trial called RMS2005 studied whether adding a lower-dose, long-term chemotherapy treatment (maintenance chemotherapy) could help patients with high-risk Rhabdomyosarcoma (RMS), a type of cancer. The trial found that this extra treatment improved survival, leading to its adoption as a standard part of care. However, researchers wanted to understand if variations in how patients received the treatment—such as differences in drug doses—affected survival outcomes.
The study analyzed data from 171 patients who received maintenance chemotherapy. It found that about 60% of patients received at least 80% of the planned drug doses. However, when researchers examined whether receiving lower or higher doses influenced survival, they found no significant impact. This suggests that small adjustments to drug doses in this treatment phase do not change overall survival chances.
The study analyzed data from 171 patients who received maintenance chemotherapy. It found that about 60% of patients received at least 80% of the planned drug doses. However, when researchers examined whether receiving lower or higher doses influenced survival, they found no significant impact. This suggests that small adjustments to drug doses in this treatment phase do not change overall survival chances.
